University of Iowa to Begin Using LUMA(R) Cervical Pre-Cancer Imaging Device

SAN DIEGO, July 23 /PRNewswire-FirstCall/ -- SpectraScience, Inc.
(OTC Bulletin Board: SCIE), a San Diego-based medical devices company, today
announced that it has placed its LUMA Cervical Imaging System to detect
pre-cancers at the University of Iowa in Iowa City, Iowa under the direction
of Dr. Colleen Kennedy.
Dr. Kennedy stated, "We are indebted to the John and Mary Pappajohn Cancer
Center Fund for their generous donation allowing us to implement the LUMA
system at the University of Iowa. We look forward to benefiting from the
enhanced productivity that it provides and, more importantly, for the ability
to provide better patient care and outcomes. We are the only medical center
currently in the mid-west providing this state-of-the art technology."
The LUMA Cervical Imaging System was developed to significantly improve
the detection of high-grade precancerous cervical abnormalities that have the
potential to become invasive cancer. Based on data from the National ALTS
study, it is estimated that precancerous disease goes undiagnosed in about
200,000 women each year.
The LUMA System provides a safe and effective method, that when used as an
adjunct to colposcopy, has been demonstrated to uncover at least 26% more
high-grade precancerous disease than colposcopy alone. The latter is the
current gold standard following an abnormal Pap test.
SpectraScience CEO Jim Hitchin commented, "We are pleased to have placed
our LUMA System at the prestigious University of Iowa facility and believe
that it is a strong validation of our technology. We are committed to
developing and bringing more effective cancer screening technologies to the
market with the result of better and earlier diagnosis."
Management estimates that the there are more than 2 million procedures
performed annually at more than 1,600 sites throughout the U.S. The
University of Iowa performs approximately 1,300 procedures annually.
SpectraScience has filed for 60 patents worldwide on its WavSTAT(R)
Optical Biopsy System and LUMA Cervical Cancer Imaging System that are used to
diagnose tissue to determine within seconds if it is normal, pre-cancerous, or
cancerous. The WavSTAT and LUMA systems are currently approved by the FDA for
detecting pre-cancer and cancer in the colon and cervix, and an evaluation for
detection of pre-cancers in the throat ("Barrett's esophagus") is being
tested.
This news release contains forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. These forward-looking
statements involve risks and uncertainties that may cause SpectraScience's
actual results to differ materially from results discussed in forward-looking
statements. Readers are urged to carefully review and consider the various
disclosures made by SpectraScience in this news release, its most recent Form
10-K and in SpectraScience's other reports filed with the Securities and
Exchange Commission ("SEC") that attempt to advise interested parties of the
risks and factors that may affect SpectraScience's business. These forward-
looking statements are qualified in their entirety by the cautions and risk
factors filed by SpectraScience in its annual report on Form 10-K and other
documents.
About University of Iowa Healthcare
University of Iowa Health Care is a fully integrated academic medical
center, uniting the UI Roy J. and Lucille A. Carver College of Medicine,
University of Iowa Hospitals and Clinics, and UI Physicians, the largest
multi-specialty group practice in Iowa. As the state's premier academic
medical center, UI Health Care provides high quality, patient-centered care,
conducts groundbreaking biomedical research, and educates the scientists and
health care providers of the future.
About SpectraScience, Inc.
SpectraScience is a San Diego based medical device company that designs,
develops, manufactures and markets spectrophotometry systems capable of
determining whether tissue is normal, pre-cancerous or cancerous without
physically removing tissue from the body. The WavSTAT Optical Biopsy System
uses light to optically scan tissue and provide the physician with an
immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for
the European Union, the WavSTAT System is the first commercially available
product that incorporates this innovative technology for clinical use. The
Company's LUMA imaging technology has received FDA approval for an optical
non-invasive system that is proven to more effectively detect cervical cancer
precursors than conventional methods available in the market today.
Contact:
SpectraScience, Inc.
Jim Hitchin, Chief Executive Officer
(858) 847-0200 x201

Hayden Communications
Investor Relations
Todd Pitcher
(858)-518-1387

SOURCE SpectraScience, Inc.

Jim Hitchin, Chief Executive Officer of SpectraScience, Inc., +1-858-847-0200,
ext. 201; or Todd Pitcher, Investor Relations of Hayden Communications,
+1-858-518-1387, for SpectraScience, Inc.